InduPro
InduPro is a Seattle-based private biotechnology company developing proximity-based protein therapeutics that modulate cell-surface protein interactions to treat cancer and autoimmune diseases, using an AI/ML-enabled membrane interactomics platform to identify novel targets and co-target pairs.
- Company typePrivate
- Founded2022
- HeadquartersSeattle, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What InduPro does
InduPro is a privately held, preclinical-to-early-clinical-stage biotechnology company founded in 2022 and headquartered in Seattle, WA, with a second office in Cambridge, MA. The company develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat cancer and autoimmune/inflammatory diseases. It was co-founded by three former Merck scientists who co-invented the photocatalytic proximity labeling technology at the Merck Exploratory Science Center that underpins the platform.
InduPro's integrated platform consists of three modules: MInt (Membrane Interactomics), an AI/ML-enabled proprietary knowledge base that catalogs inherently proximal surface proteins using deep learning analysis of membrane proteomic data and identifies novel targets and co-target pairs; ARRIS (Proximity Modalities), a multi-specific antibody platform that uses induced proximity to bring cell-surface proteins into therapeutic configurations; and Therapeutic Engineering (TE), which provides internal antibody discovery, protein characterization, and optimization. The proprietary TAPA discovery engine identifies tumor-associated proximity antigens enabling selective co-targeting of tumor cells. The pipeline comprises oncology bispecific ADCs (IDP-001 co-targeting EGFR and TAPA-E1, IND filing planned Q1 2026; IDP-012 with topoisomerase 1 inhibitor payload; IDP-004 targeting MET and TAPA-M1), a PD-1 antagonist (IDP-002), and a PD-1 agonist (IDP-003) partnered with Sanofi for autoimmune indications.
InduPro is pre-revenue and operates a partnership-driven enterprise business model. The company secures strategic equity investments, R&D funding, milestone payments, and royalties through multi-program licensing deals with major pharmaceutical partners. In June 2024 it closed an $85 million Series A co-led by The Column Group and Vida Ventures. In December 2025 it announced a strategic equity investment and research collaboration with Sanofi for the bispecific PD-1 agonist program. In January 2026 it entered a global strategic collaboration with Eli Lilly covering up to three targets for total deal value of up to approximately $950 million. CEO Prakash Raman, Ph.D., joined in April 2024 from Ribon Therapeutics, with additional leadership across CSO/President Scott Lesley, Ph.D. (former Merck VP of Discovery Biologics), CMO Amanda J. Redig, M.D., Ph.D., and VPs spanning biology, chemical sciences, platform technology, biologics, operations, finance, and corporate development.
InduPro firmographics
Firmographics- Name
- InduPro
- Legal name
- InduPro, Inc.
- Website
- https://induprotx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- InduPro is a Seattle-based private biotechnology company developing proximity-based protein therapeutics that modulate cell-surface protein interactions to treat cancer and autoimmune diseases, using an AI/ML-enabled membrane interactomics platform to identify novel targets and co-target pairs.
- Ownership category
- akta.pro rank
InduPro industry classification
Industry- Product category
- Biotechnology Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where InduPro is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Markets served
InduPro business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Strategic Collaboration & Licensing Fees: Multi-year, multi-program licensing deals with global pharma partners (Eli Lilly up to ~$950M total deal value across up to three targets; Sanofi for bispecific PD-1 agonist), typically structured with upfront payments, R&D funding, milestone payments tied to development/regulatory/commercial events, and potential royalties on commercialized products.
- Pharma-Funded Preclinical/IND-Enabling Research: Research funding from pharma partners (e.g., Sanofi funding preclinical and IND-enabling research activities on the PD-1 agonist program) for collaborative R&D execution.
- Venture Equity Financing: Pre-revenue company; primarily funded to date by venture equity ($85M Series A in 2024 plus additional equity investments from strategic partners Sanofi and Eli Lilly) used to advance pipeline and platform. Not operating revenue but primary capital inflow prior to licensing income.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Outcome Based/ Performance | Multi-year contract | Eli Lilly collaboration: total deal value up to approximately $950 million across up to three targets, including equity investment, plus potential royalties (terms not fully disclosed) |
| Outcome Based/ Performance | Multi-year contract | Sanofi collaboration: equity investment (undisclosed) plus research funding for preclinical/IND-enabling activities; right of first negotiation for the bispecific PD-1 agonist program |
Go-to-market motion2 records
InduPro product offering
Product offeringCore offering
InduPro develops proximity-based protein therapeutics that leverage inherent and induced cell-surface protein proximity to treat cancer and autoimmune diseases. The company operates a proprietary induced-proximity drug discovery platform (MInt, ARRIS and Therapeutic Engineering) and advances a pipeline of first- and best-in-class bispecific antibody candidates, including antibody-drug conjugates (ADCs), T-cell engagers, and PD-1 modulators, which it licenses to large pharmaceutical partners via multi-year strategic collaboration deals.
Product overview
InduPro offers a single, unified induced-proximity drug discovery platform composed of three core platform modules — MInt (Membrane Interactomics), ARRIS (Proximity Modalities), and Therapeutic Engineering (TE) — that work together end-to-end: MInt catalogs inherent cell-surface protein proximity via AI/ML to identify novel targets and co-target pairs; ARRIS uses multi-specific antibody technology to design induced-proximity therapeutics against those targets; and Therapeutic Engineering provides the in-house antibody discovery, protein characterization, and optimization capabilities that translate those designs into clinical molecules. The platform fuels InduPro's pipeline of first- and best-in-class bispecific candidates, including oncology programs IDP-001 (EGFR x TAPA-E1 bispecific ADC), IDP-012 (EGFR x TAPA-E1 bispecific ADC with topoisomerase 1 inhibitor payload), IDP-004 (MET x TAPA-M1 bispecific ADC), the immuno-oncology program IDP-002 (PD1 antagonist), and the autoimmune program IDP-003 (PD1 agonist, partnered with Sanofi).
Differentiator
Problem solved
Functional benefit
Products and services
- IDP-001 First-in-class, proximity-based bispecific antibody-drug conjugate (ADC) co-targeting EGFR and a novel tumor-associated proximity antigen (TAPA-E1) for oncology; IND filing planned for Q1 2026.
- IDP-012 Bispecific ADC with a topoisomerase 1 inhibitor payload co-targeting EGFR and TAPA-E1 in oncology.
- IDP-004 Bispecific ADC co-targeting MET and a novel tumor-associated proximity antigen (TAPA-M1) in oncology.
- IDP-002 Best-in-class bispecific PD-1 antagonist (PD1 x T-Cell Antigen 1) offering superior receptor occupancy through cooperative binding, independent of VEGF; enhances T-cell signaling while limiting Treg co-activation.
- IDP-003 Differentiated bispecific PD-1 agonist (PD1 x T-Cell Antigen 2) that recruits PD1 into the immune synapse via a non-depleting, FcR-independent mechanism; partnered with Sanofi for autoimmune and inflammatory disorders.
Companies that use InduPro
Customer profileIdeal customer profiles1 record
InduPro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
InduPro partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights6 records
InduPro competitors and assessment
Company assessmentDirect peers
- HotSpot Therapeutics: Preclinical/early-clinical biotech developing induced-proximity therapeutics, including small-molecule CBL-B inhibitors, sharing InduPro's core concept of leveraging induced proximity for therapeutic effect. Comparable in stage, mechanism philosophy, and partnership-driven business model.
- Ribon Therapeutics: Oncology biotech founded by scientists from the same academic/biopharma network as InduPro's founders and leadership. Ribon's CEO and CFO (Prakash Raman and Jeff Palmer) previously held leadership roles at Ribon before joining InduPro, making it a closely comparable oncology-focused private biotech.
- Xilio Therapeutics: Clinical-stage immuno-oncology company developing tumor-selective bispecifics and cytokines. Comparable in stage and size, with shared leadership pedigree (Ertan Eryilmaz was previously VP of Biologics at Xilio before joining InduPro) and similar focus on selective tumor targeting.
- Alpine Immune Sciences: Biotech developing engineered protein therapeutics for autoimmune and inflammatory diseases using directed evolution and Fc-engineering. Comparable in autoimmune/immuno-oncology focus and bispecific modality, with overlapping leadership background (Pam Holland was previously SVP of Research at Alpine).
- Janux Therapeutics: Clinical-stage biotech developing T cell engager (TCE) bispecifics for oncology, directly overlapping with InduPro's TAPA-based TCE programs. Comparable in modality (bispecifics), indication focus (oncology), and partnership-driven strategy.
- Cullinan Oncology: Clinical-stage oncology company developing a diversified pipeline of targeted therapies including bispecifics. Comparable as a private/early-public oncology biotech at similar stage and scale pursuing selective tumor-targeting approaches.
- Surface Oncology: Immuno-oncology biotech developing therapeutics targeting the tumor microenvironment. Comparable in indication focus (oncology), modality (antibody-based biologics), and team pedigree (Pam Holland was previously VP of Cancer Biology at Surface).
Broad incumbents
- Arvinas: Clinical-stage leader in targeted protein degradation (PROTACs), a related induced-proximity modality that uses bifunctional small molecules rather than antibodies. Comparable as an induced-proximity platform company but at significantly more advanced clinical stage and larger scale.
- Kymera Therapeutics: Clinical-stage biotech developing heterobifunctional degraders (induced proximity via small molecules). Comparable platform philosophy and oncology/immunology focus, though at a more advanced clinical stage and with public-company scale and capital.
- Genmab: Public biotech with a leading bispecific antibody platform (DuoBody) and approved assets including epcoritamab. Directly comparable in bispecific antibody technology and oncology/autoimmune focus, but operates as a broad incumbent across multiple platforms and programs rather than a single-platform specialist.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
InduPro social profiles
Digital presenceInduPro financial estimates
Financial estimateRevenue estimate
Valuation estimate
InduPro leadership team
Management profileNumber of profiles
Profiles11 records
InduPro funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InduPro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InduPro
What does InduPro do?
InduPro develops proximity-based protein therapeutics that leverage inherent and induced cell-surface protein proximity to treat cancer and autoimmune diseases. The company operates a proprietary induced-proximity drug discovery platform (MInt, ARRIS and Therapeutic Engineering) and advances a pipeline of first- and best-in-class bispecific antibody candidates, including antibody-drug conjugates (ADCs), T-cell engagers, and PD-1 modulators, which it licenses to large pharmaceutical partners via multi-year strategic collaboration deals.
Is InduPro a public or private company?
InduPro is a private company. It is classified as venture growth investor backed and is currently operating.
When was InduPro founded?
InduPro was founded in 2022. It employs 51 to 100 people.
Where is InduPro based?
InduPro is headquartered in Seattle, United States, in the North America region.
How does InduPro make money?
Three revenue lines are on record. Strategic Collaboration & Licensing Fees are the primary driver. The others are pharma-Funded Preclinical/IND-Enabling Research and venture Equity Financing.
Who are InduPro's main competitors?
Direct peers on record are HotSpot Therapeutics, Ribon Therapeutics, Xilio Therapeutics, Alpine Immune Sciences, Janux Therapeutics, Cullinan Oncology and Surface Oncology. Broad incumbents are Arvinas, Kymera Therapeutics and Genmab.
Does InduPro have an API?
No public API is recorded for InduPro.
What industry is InduPro in?
InduPro's product category is Biotechnology Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 3254 and its SIC code is 2834.